September 23, 2021 08:29 AM EDTUpdated September 29, 09:05 AM
Coronavirus
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: Bharat Biotech turns to oth­er pro­duc­ers to up sup­ply; Brazil, Ar­genti­na land mR­NA re­gion­al hubs

Josh Sullivan

Bharat Biotech is ready to start man­u­fac­tur­ing dos­es of its Covid-19 vac­cine — named Co­v­ax­in — at an as­so­ciate firm’s Man­jari site, Busi­ness-Stan­dard

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times